The 
INTRODUCTION
The macrophage migration inhibitory factor (MIF) was one of the first cytokines to be described and has since been implicated in many diseases including infectious diseases and cancer [1] . D-Dopachrome tautomerase (D-DT) shares 27 % sequence identity with MIF and X-ray analysis have revealed a highly conserved tertiary structure to MIF. However, the biological functions of D-DT have remained unclear for a long time [2, 3] . Recently, we and others have described functional overlaps between MIF and D-DT [4] [5] [6] . Both MIF and D-DT bind to the receptor CD74 and induce ERK1/2 phosphorylation, leading to macrophage migration arrest and counterregulation of glucocorticoid-induced immunosuppression [4] . In lung cancer cells, both MIF and D-DT contribute to CXCL8 and VEGF production, two important factors for tumor progression and angiogenesis [5] . Together with the finding that D-DT, as MIF, induces COX-2 expression through stabilization of β-catenin [6] , these findings are strongly suggestive of a pro-tumorigenic role of D-DT, as previously demonstrated for MIF [7] .
Analysis of clinical samples further showed that D-DT, like MIF, is elevated in sera of patients suffering from ovarian cancer and a correlation between D-DT levels and disease progression has been reported [4] .
In cancer cells, MIF seem to play both an autocrine and paracrine role for tumor cell survival and invasiveness [8, 9] . In a MIF-null environment, tumor growth is significantly delayed and part of this effect is mediated by inefficient recruitment of pro-tumoral regulatory cell populations [7, 10] . The important role of MIF in tumor progression has led to the development of MIF-antagonizing or MIF-neutralizing strategies for the treatment of cancer. As a consequence, MIF-inhibitory small molecules and MIF-neutralizing antibodies are currently in preclinical development [10, 11] .
Because MIF and D-DT have similar biological functions, we hypothesized that D-DT neutralizing therapeutic strategies may have a similar impact on tumor biology as demonstrated for MIF. We analyzed two aggressive murine tumor models for D-DT secretion in vitro and in vivo. We provide first evidence that mice are a suitable model for the analysis of D-DT in cancer. Furthermore, we demonstrate that the depletion of D-DT via siRNA or neutralization via antibodies results in reduced tumor growth. Therefore these strategies may be developed as a treatment modality against cancer. 
D-DT silencing reduces proliferative capacity of murine melanoma cells
MIF mediates cell proliferation and protects tumor cells from apoptosis [9, 11] . We thus hypothesized a similar role for D-DT, which would qualify D-DT as a therapeutic target. We designed specific siRNA against D-DT which mediated a significant knock-down of D-DT on the protein level in B16F10 cells ( Figure 2A) . Importantly, no impact on MIF expression could be observed (data not shown).
Knock-down of D-DT resulted in a significant decrease in cell proliferation compared to a decoy siRNA ( Figure 2B ). This decrease in cell proliferation was not due to a reduced cell viability or an increase in cell death (data not shown). Next, we induced apoptosis in B16F10 cells by treating with staurosporin after D-DT silencing. After depletion of D-DT, we observed an increase of apoptosis in comparison to control groups ( Figure 2C ).
D-DT neutralization slows tumor progression in vivo
Finally, we tested if D-DT neutralization impacts on tumor growth in vivo. We purified polyclonal D-DT antibodies from immunized rabbit serum by affinity chromatography using the recombinant antigen. Affinitypurified D-DT antibodies or polyclonal rabbit IgG were administered at a dose of 250 µg per mice every second day from tumor injection (n = 4 mice per group). While MIF expression has been demonstrated in a wide variety of tumors [1] . In contrast, D-DT expression so far has been evaluated in healthy tissues and only a few cancer models such as lung and colon cancer. In these cell lines a similar expression pattern as MIF has been observed [2, 4] . Therefore, it was not surprising that D-DT is expressed and secreted in the melanoma cell line B16F10 and in the breast cancer cell line 4T1. However, we observed differences between in vitro and in vivo D-DT production: in vitro, D-DT secretion is higher in B16F10 cells, as opposed to in vivo where D-DT serum levels were higher in mice bearing 4T1 tumors. One possible explanation for this discrepancy may be an additional cellular source of D-DT induced by the growing tumors. In fact, immune cells such as myeloid cells are an established source of MIF and D-DT production. These cells play an important role in the biology of these tumor models [12] . The 4T1 tumor model induces a heavy expansion of the myeloid compartment leading to marked splenomegaly and to strong myeloid infiltrates at the tumor sites, both of which may account for the increased D-DT serum levels [12] . In summary, we demonstrate that D-DT may be a suitable target for cancer therapy [11] . Possible formats would be systemic administration of siRNA or monoclonal neutralizing D-DT antibodies, both of which need to be established. It will be interesting to know if our observations in a murine system will also translate in human cancer models and thus warrant further preclinical analysis of D-DT as a therapeutic target.
MATERIALS AND METHODS

Cell lines
The murine melanoma cell line B16F10 was cultured in DMEM with 10% fetal bovine serum (FBS, Life Technologies, USA), 1% penicillin and streptomycin (PS) and 1% L-glutamine (all from PAA, Germany). The murine breast cancer cell line 4T1 was provided by M. Wartenberg (Jena, Germany) and cultured in RPMI 1640 with 10% FBS, 1% PS and 1% L-glutamine.
Animal experiments
Wild type C57BL/6RJ and Balb/cJ mice were purchased from Janvier (St. Berthevin, France). B16F10 and 4T1 tumors were induced by injecting 5 x 105 or 106 tumor cells per mice, respectively. 250 µg of affinitypurified polyclonal rabbit D-DT antibody or polyclonal rabbit IgG were injected i.p. every second day. All animal studies were approved by the local regulatory agency (Regierung von Oberbayern).
D-DT ELISA
D-DT ELISA was constructed with in-house antibodies and was performed as described [4] . In brief, recombinant D-DT was sent to the SEQLAB-Sequence laboratories (Göttingen, Germany) where it was used to immunize rabbits. Anti D-DT rabbit serum antibodies were recovered using affinity chromatography with binding to recombinant D-DT bound on HiTrap-NHS columns (GE Healthcare, Freiburg, Germany), were eluted and thereafter dialyzed against PBS.
Western blot
Polyclonal rabbit D-DT antibody was generated and used for Western blot as described [4, 13] .
Reverse transcriptase polymerase chain reaction
Reverse transcription and polymerase chain reaction was performed as described [13] using the following primer sequences: CD74-fwd: 5'-GCA GTG GCT CTT GTT TGA GA-3', CD74-rev: 5'-TTC CTG GCA CTT GGT CAG TA-3', CXCR2-fwd: 2 5'-CAG GAC CAG GAA TGG GAG TA-3', CXCR2-rev: 5'-TCC CCT CCA AAT ATC CCC TA-3', CXCR4-fwd: 5'-TGG AAC CGA TCA GTG TGA GT-3', CXCR4-rev: 5'-GGG CAG GAA GAT CCT ATT GA-3', β-Actin-fwd: 5'-CTA AGG CCA ACC GTG AAA AG-3', β-Actin-rev: 5'-ACC AGA GGC ATA CAG GGA CA-3' siRNA lipofection and proliferation assay siRNA lipofection was performed as described [14] with the following siRNA pairs: D-DT-sense 5'-CUU GGC AGA UCG GAA AG-3' and D-DT-antisense 5'-UUC UUU CCG AUC UGC CAA G-3'. A decoy siRNA served as control: 5'-GCG CAU UCC AGC UUA CGU A-3'. BrdU-proliferation assay (Roche, Mannheim, Germany) was performed according to the manufacturer´s instructions.
Apoptosis assay by annexin V-propidium iodide staining
Analysis of apoptosis was performed as described [13] . Staurosporin (Sigma, Munich Germany) was used as indicated.
Statistics and data analysis
For statistics GraphPad Prism software, version 5.0b was used. All t-tests were two-tailed and p-values < 0.05 were considered significant. Differences between experimental conditions were analyzed using the unpaired Student´s t-test. For in vivo experiments, differences between groups were analyzed using two-way ANOVA with correction for multiple testing.
